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A novel diagnostic approach to a mass on a device lead
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Alex K. Williamson, MD,‡ Haisam Ismail, MD,* Laurence M. Epstein, MD*
From the *Division of Electrophysiology, Department of Cardiology, North Shore University Hospital,
Northwell Health, Manhasset, New York, †Division of Echocardiography, Department of Cardiology,
North Shore University Hospital, Northwell Health, Manhasset, New York, and ‡Department of
Pathology, North Shore University Hospital, Northwell Health, Manhasset, New York.
Introduction
Utilization of cardiovascular implantable electronic devices
(CIEDs), including pacemakers and cardioverter-deﬁbrillators,
as a therapeutic modality for cardiac arrhythmias is vastly ex-
panding in the setting of an aging patient population. More
than 200,000 devices were implanted in the United States in
2006 and over 3 million patients worldwide currently have
CIEDs.1 While a great deal of focus is placed on advances in
technology and clinical efﬁcacy of the devices, prompt diag-
nosis and management of device infections and thrombi on
transvenous leads are also important. Large clinical registries
such as the Denmark registry have shown a 1.83% incidence
of device infection leading to a CIED removal.2 The incidence
of thrombi on device leads has been reported to be as a high as
48% of atrial leads and 33% of ventricular leads on autopsies.3
Finding an echogenic mass on a device lead is reported to
occur in 14% of leads imaged by echocardiography.4 Despite
this relatively high incidence, determining the etiology of the
mass in certain clinical settings remains challenging. For
example, echocardiography may reveal lead-associated
masses or vegetations in patients without other signs or symp-
toms of a systemic infection or venous thromboembolism. As
a result, ﬁnding a mass of uncertain etiology on a device lead
may result in unnecessary and/or delayed treatments.
Discovering amass on a device lead is expected to bemore
common as more devices are implanted. Case reports on
various techniques such as using a triple-loopwire snare to bi-
opsy a lead-associated mass have been published; however,
the literature on this topic remains scant.5 We present 2 cases
in which a novel diagnostic method was used in patients with
masses on their device leads. In both cases, a transesophageal
echocardiogram (TEE)-guided biopsy of the mass was per-
formed utilizing a bioptome introduced through a steerable
sheath via the femoral vein. An experienced echocardiog-
rapher utilized a combination of primarily bicaval view of
the right atrium in 2-dimensional TEE and ﬂuoroscopy in
both cases. The leads could be differentiated by targeting
each lead on ﬂuoroscopy with the bioptome and watching
the motion on TEE. Since most electrophysiologists are
more comfortable guiding catheters with ﬂuoroscopy, we
used a combination of both approaches. Once each lead was
identiﬁed on TEE, the location of the mass on the lead was
conﬁrmed. The bioptome was then positioned to that portion
of the lead by ﬂuoroscopy. The bioptome was moved in and
out of view on TEE to identify the tip. Moving the lead while
grasping the mass, but not the lead, helped conﬁrm location.
Although not excessive, traction can be applied to the lead, so
care should be taken with newly implanted leads.
The samples were sent to histology, gram stain, and cul-
ture, allowing for a prompt diagnosis. Our patients were
started on appropriate treatment based on the biopsy results
and both had good clinical outcomes.
Case report
Case 1
An 80-year-old woman with a remote history of breast cancer
and a dual-chamber pacemaker implanted 2 years prior for
sick sinus syndrome presented to another hospital for pro-
gressively worsening vision in her left eye for 3 weeks. A
computed tomography angiography was done, revealing a
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90% stenosis of her left internal carotid artery and an inci-
dental ﬁnding of a mass on her right atrial (RA) lead. A
TEE conﬁrmed the presence of the 1.6 ! 1.0-cm mass.
The patient had a mild leukocytosis in the setting of a recent
dental procedure but was afebrile, with negative blood
cultures. She was started on unfractionated heparin and intra-
venous antibiotics and transferred to our hospital for a device
extraction. She had no clinical ﬁndings suggestive of an
infection or a recurrence of her malignancy but was
continued on antibiotics and anticoagulation. A biopsy was
performed in an effort to determine the etiology of the
mass on her RA lead. Femoral access was obtained and an
Agilis NxT Steerable Introducer (Abbott, St. Paul, MN)
was advanced under ﬂuoroscopy into her right atrium. A
2.4 mm ! 105 cm, 7.5F Argon bioptome (Argon Medical
Devices, Athens, TX) was employed under TEE guidance
and 10 biopsy specimens of the RA lead mass were obtained
(Figure 1A–C). She tolerated the procedure well, with no sig-
niﬁcant changes in the sensitivity, impedance, and pacing
threshold of the RA lead. The lead was not dislodged on ﬂuo-
roscopy and follow-up chest radiograph. Pathology results
returned within hours of the procedure and conﬁrmed that
the mass was a thrombus with irregular fragments of soft tis-
sue (Figure 1D). The gram stain showed no polymorphonu-
clear cells and the tissue culture conﬁrmed no growth.
Antibiotics were discontinued and the patient was transi-
tioned to oral anticoagulation. She did not require a device
extraction and was safely discharged on anticoagulation.
On follow-up imaging, the mass had signiﬁcantly decreased
in size and the patient was cleared for carotid surgery.
Case 2
A 29-year-old man with a history of a resected chest wall der-
matoﬁbrosarcoma and a primary-prevention implantable
cardioverter-deﬁbrillator (ICD) implanted 10 years prior for
Brugada syndrome presented with 1 week of intermittent
fevers and night sweats followed by syncope. A computed
tomography angiography of the chest showed multifocal
acute pulmonary emboli (PE) within the bilateral upper and
lower segmental branches. A transthoracic echocardiogram
followed by a TEE revealed a mass in the right atrium and
right ventricle of 2.9 cm ! 1.2 cm, encasing the device
lead, suggestive of a thrombus. A single blood culture from
Figure 1 Transesophageal echocardiography–guided biopsy of thrombus on a device lead. A–C: Bicaval transesophageal echocardiogram views of the
thrombus on the right atrial lead. The asterisk denotes the thrombus. Blue arrows point to the lead. The red arrow in panel C is the bioptome in close proximity
to the thrombus. D: Intracardiac mass, hematoxylin–eosin stain,!200. Haphazard admixture of erythrocytes, ﬁbrin, and neutrophils, consistent with thrombus.
IVC 5 inferior vena cava; RA 5 right atrium; SVC 5 superior vena cava.
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admission grew a Propionibacterium species that was
thought to be a contaminant. In the setting of persistent
low-grade fevers and leukocytosis, he was treated with both
unfractionated heparin for PE and intravenous antibiotics
for possible culture-negative endocarditis. The patient had
multiple subsequent negative blood cultures, which were
held for extended growth; and owing to a low clinical suspi-
cion for infection, antibiotics were discontinued. To conﬁrm a
presumed diagnosis of thrombus, the right ventricular mass
was biopsied using the same technique as the previous case
(Figure 2). Fifteen tissue samples were collected with the bio-
ptome. The patient’s right ventricular lead sensitivity, imped-
ance, and pacing threshold were unchanged following the
biopsy and the lead was not dislodged on ﬂuoroscopy and
subsequent chest radiograph. Pathology resulted 24 hours
after the procedure and revealed pieces of ﬁbrin mixed with
neutrophils harboring calciﬁcations, consistent with an infec-
tious etiology (Figure 2D). Antibiotics were resumed and the
patient underwent lead extraction. Culture of the extracted
ICD lead tip was positive for the same Propionibacterium
species as the single isolate from the initial blood cultures
that were originally thought to be a contaminant. He was
treated with an extensive course of antibiotics and received
a subcutaneous ICD prior to discharge.
Discussion
With the advancement in CIEDs, the implantation rate has
been increasing, with a recent study reporting over a million
device implantations in 2017 worldwide.6 Device infection
rates have also increased out of proportion to the number of de-
vices implanted.7 Infection can cause device malfunction and
clinical complications such as PE and bacteremia. Studies
have shown that early diagnosis of device infection and lead
extraction within 3 days are associated with decreased mortal-
ity. A delay in treating a device infection is associated with a
30-day mortality of 5.5% and a 1-year mortality of 14.6%.6
Owing to poor clinical outcomes in patients with device-
related infections, even in the absence of clinical signs or
symptoms of an infection, the practical approach is to start
Figure 2 Transesophageal echocardiography–guided biopsy of a vegetation on a device lead.A–C:Midesophageal 4-chamber views at 0 degrees of the vege-
tation on the right ventricular lead. The asterisk denotes the vegetation. Blue arrows point to the lead. The red arrow in panels B and C is the bioptome sampling
the vegetation. D:Mass on right ventricular lead, hematoxylin–eosin,!40. Aggregates of ﬁbrin admixed with neutrophils and basophilic debris with few eryth-
rocytes, consistent with vegetation. Special stains (Gram, periodic acid–Schiff, and Gomori methenamine silver) for organisms were negative. LA5 left atrium;
LV 5 left ventricle; RA 5 right atrium; RV 5 right ventricle; TV 5 tricuspid valve.
308 Heart Rhythm Case Reports, Vol 5, No 6, June 2019
empiric antibiotic therapy in patients with a mass on their
device lead. However, not all masses on device leads are infec-
tious in etiology.
As seen in our 2 cases, determining the etiology of the
mass and initiating the appropriate management can be chal-
lenging. Difﬁculty in making a timely diagnosis may lead to
delays and potentially unnecessary treatments. To solve this
problem, we propose a novel diagnostic approach that allows
for pathology results to make the diagnosis within 24 hours.
We utilized a bioptome with TEE and ﬂuoroscopic guidance
to directly biopsy masses of uncertain etiology on device
leads. Three-dimensional (3D) TEE was not deemed neces-
sary in both cases, as 2-dimensional TEE and ﬂuoroscopic
images clearly delineated the bioptome and the lead masses.
Cardiac anesthesiology experienced in TEE may be con-
sulted for difﬁcult cases such as mobile masses.
In our ﬁrst case, antibiotics were discontinued as soon as
the pathology report of the biopsy conﬁrmed thrombus. This
circumvented a possible long-term course of antibiotics as
well as a device extraction. In our second case, antibiotics
were prematurely discontinued owing to a presumptive diag-
nosis of thrombus. When the biopsy conﬁrmed an infectious
process, the patient was restarted on the antibiotics and the
device was extracted prior to potential complications of a sys-
temic infection. Both cases highlight the beneﬁt of utilizing
our diagnostic approach with a bioptome to identify the etiol-
ogy of a mass on a device lead.
It is important to compare our biopsy approach to what has
been published in the literature. A case of infective endocardi-
tis has been reported in which a triple-loop wire snare (Atrieve
vascular snare, Angiotech,Vancouver, British Columbia, Can-
ada) was used under TEE to completely remove amass of 2.41
cm in length on the RA lead inserted in 1996.5 Histology
conﬁrmed a noninfected thrombus and the patient was treated
for a long-term anticoagulation without lead extraction. The
patient had no recurrence of thrombus, nor infectious etiology.
A triple-loopwire snaremay be a useful diagnostic tool that en-
ables complete removal of a leadmass, but the disadvantage of
the snare compared to the bioptome is the lack of control in
maneuvering the snare around a lead mass. In addition, the
snare is more likely to disrupt the mass than a bioptome,
sending emboli to the lungs.
Imaging modalities may also play a role in differentiating
a lead mass. Two case reports utilized 18F-ﬂuorodeoxyglu-
cose positron emission tomography scans.5,8 In both cases,
the low level of glucose metabolism around the lead helped
make the diagnosis of thrombus rather than vegetation. One
of the cases also involved 3D TEE to better visualize the
lead mass.5 However, the diagnosis was not deﬁnitive until
the pathologic studies were done, which points back to the
importance of the biopsy of the lead mass.
While the safety of the approach still needs further inves-
tigation, our 2 cases demonstrated that the biopsy samples
can be obtained directly from the lead without affecting the
lead parameters. The dwell time for the leads in our patients
were 2 and 10 years. As is the case with any lead manipula-
tion, performing a biopsy of a lead-associated mass using the
technique described above carries a risk of lead dislodge-
ment, especially in leads with shorter dwell times.
Conclusion
In clinical practice, it is not uncommon to encounter a lead-
associated mass by echocardiography. Differentiating a
vegetation from a thrombus can be challenging in certain
clinical scenarios.We report, to our knowledge, the ﬁrst cases
of a bioptome being used to sample tissue from
lead-associated masses. We highlight how important the
pathologic diagnoses were to the patients’ care. The biopsy
prevented an unnecessary extraction in 1 case and facilitated
an appropriate extraction in the other. This novel technique
can be performed safely without affecting the integrity of
the lead, as seen in our cases. Accurately and promptly diag-
nosing a lead mass utilizing innovative tools such as a bio-
ptome and a wire snare, as well as imaging modalities such
as a 3D TEE and a positron emission tomography scan, needs
more experience and further discussion, as there is limited
literature on the topic.
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